Open original FDA record ↗Recall record
- FDA identifier
- Z-1365-2020
- Company in FDA record
- BIOMERIEUX - Grenoble
- FDA classification date
- Feb 11, 2020
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Following a customer complaint about colored eluates, leading to invalid results bioMerieux has confirmed an issue with NUCLISENS Lysis Buffer, ref. 200292, lot 19040201. The issue is linked to drift of pH electrode dysfunction.
Source facts
- Action
- Consignees notified via FedEx Express 2 day delivery service with recall letter dated 10 January 2020. The letter identified affected product, stated reason for recall, and requested product to not be used for testing of whole blood samples containing blood and other specimens containing blood. Samples with no hemoglobin are not impacted by the issue and can be used with expected performance. A Recall Acknowledgement Form was requested to be completed and returned via fax.
- Initiated
- 2020-01-10
- Root cause
- Equipment maintenance
- Terminated
- 2022-04-14
- Distribution
- No US distribution. No Mexican consignees. International distribution to South Africa, Uruguay, Tanzania, Romania, Netherlands, Macao, Italy, India, Hong Kong, United Kingdom, France, Spain, Germany, China, Chile, Canada, Belgium, Australia, Argentina, Curacao.
- Recall number
- Z-1365-2020
- Recall status
- Terminated
- CDRH record ID
- 179301
- FDA classified
- 2020-02-11
- Recall event number
- 84766